Similar with our results, Shilkrut et al. [17] recently reported that the expression of RRM1, but not ERCC1, may predict response to gemcitabine-based chemoradiotherapy and worse cancer-specific survival in patients with muscle-invasive UC. This evidence concerns the gene ERCC1 and cancer.